Company Team Search Site Map Careers Privacy Statement
:: Home
:: About Us
:: R&D
:: Products
:: Services
:: Infrastucture
:: Contact us
Virchow Products

Welcome to Virchow Biotech Private Limited (VBPL), an innovative biotechnology company headquartered at Hyderabad, India. VBPL also has offices located in the United States of America (at Nashville, Tennessee)

With an aim of establishing itself in the sunrise industry of biotechnology, Virchow Biotech (P) Ltd commenced its Indian operations in the year 2001. The focus was to develop and manufacture a wide range of unique biologicals and high value bio-generic products at an affordable price. Since then we made impressive strides in terms of product development and have built a strong foundation with a commitment to innovation and process efficiencies. We have rapidly cornered a name for ourselves as a developer of cutting edge therapies in this rapidly evolving biotechnology space.

Our first mover strategy has enabled us to aggressively capture a lucrative niche in the therapeutic areas of recombinant medicines, advanced wound care products, Hemostats, ophthalmic; orthopaedic and cosmetics amongst others.

We have the credit of being the first company in the World to commercialize the biogenerics of recombinant Platelet Derived Growth Factor for wound healing and recombinant Parathyroid Hormone for osteoporosis. We also have a product portfolio consisting of 15 other niche products and five other recombinant bio-generics in pipeline.

We are a multi-faceted company, focusing not only on biotechnology innovation but also on training and developing the best and brightest scientific manpower. This combination of good scientists given the freedom and necessary resources, we believe, will lead to the generation of breakthroughs and ultimately result in the advancement of science that benefits mankind.

Please browse through our web pages and check back frequently as our website will be undergoing constant change reflecting the dynamic nature of our company. Do not hesitate to contact us for more information.

We will be glad to hear from you…

News & Events

Virchow Biotech is filing for U.S.Food and Drug administration’s (FDA) approval for its in house developed advanced wound care products.

Virchow Biotech received Drug control’s (DCGI) approval for conducting clinical trials on periogen, an indigenously developed recombinant therapeutic product for periodontal diseases

Virchow Biotech and Ranbaxy signed an MOU to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment. We are the first in the world to launch this biogeneric product